Author/Authors :
saviano, antonio institut de recherche sur les maladies virales et hépatiques (ivh), Strasbourg, France , saviano, antonio hôpitaux universitaires de strasbourg - institut hospitalo-universitaire, Strasbourg, France , saviano, antonio university of strasbourg, Strasbourg, France , tripon, simona institut de recherche sur les maladies virales et hépatiques (ivh), Strasbourg, France , tripon, simona hôpitaux universitaires de strasbourg - institut hospitalo-universitaire, Strasbourg, France , baumert, thomas f. institut universitaire defrance (iuf), Paris, France , baumert, thomas f. university of strasbourg, Strasbourg, France , baumert, thomas f. hôpitaux universitaires de strasbourg - institut hospitalo-universitaire, Strasbourg, France , baumert, thomas f. institut de recherche sur les maladies virales et hépatiques (ivh), Strasbourg, France
Abstract :
Editorial: Hepatitis C virus (HCV) is a main cause and important risk factor for hepatocellular carcinoma (HCC) in Western countries (1). Direct antiviral agents (DAAs) for HCV are highly effective and well-tolerated antiviral drugs which allow HCV cure even in patients with advanced liver disease. However, whilst HCV cure improves liver function and decreases overall HCC risk, a significant HCC risk persists in particular in patients with advanced fibrosis including cirrhosis who have the highest risk of developing HCC (2-4).
